Table 1: Twelve studies selected as sitagliptin as mono therapy group (group 1).

Study

Design

Dose

Control

Follow-up

N1

Baseline HbA1c % (SE %)

Change of HbA1c % (SE %)

Aschner 20062 [14]

R, DB3

100 mg QD4

Placebo

24wk

229

8.01 (0.88)

-0.61 (0.064)

Goldstein 2007 [15]

R, DB

100 mg QD

Placebo

24wk

175

8.87 (0.99)

-0.66 (0.084)

Hanefeld 20072 [16]

R, DB

100 mg QD

Placebo

12wk

106

7.78 (0.90)

-0.44 (0.071)

 

50 mg BID

Placebo

108

7.79 (0.85)

-0.43 (0.068)

Mohan 2009 [17]

R, DB

100 mg QD

Placebo

18wk

339

8.7 (1.0)

-0.7 (0.051)

Nonaka 2008 [18]

R, DB

100 mg QD

Placebo

12wk

75

7.54 (0.85)

-0.65 (0.077)

Raz 20062 [19]

R, DB

100 mg QD

Placebo

18wk

193

8.04 (0.82)

-0.48 (0.066)

Scott 2007 [20]

R, DB

50 mg BID

Placebo

12wk

121

7.83 (0.95)

-0.54 (0.071)

Barzilai 2011 [21]

R, DB

100 mg QD

Placebo

24wk

101

7.8 (0.8)

-0.50 (0.128)

Iwamoto 2010  [22]

R, DB

50 mg QD

Voglibose

12wk

155

7.7 (0.9)

-0.70 (0.051)

Aschner 2010 [23]

R, DB

100 mg QD

Metformin

24wk

455

7.2 (0.7)

-0.43 (0.051)

Perez-Monteverde 2011 [24]

R, DB

100 mg QD

Pioglitazone

12wk

231

9.0 (1.4)

-1.00 (0.077)

Chan 20082 [25]

R, DB

100 mg QD

Placebo/Glipizide

12wk

55

7.6 (0.9)

-0.60 (0.102)

 

1N: number of patients available for computing change of HbA1c if reported, and number of randomized patients otherwise.
2Studies have different dose groups of Sitagliptin. If there is a group of 100mg (once per day), we used data for this group; and used data for the group with maximum dose otherwise. For Hanefeld et al. (2007), we kept two groups (100mg once per day or 50mg twice per day). Chan 2008 have multiple follow-up visits, and we used the visit closest to 24 weeks.
3R: randomized; DB: double-blinded
4QD: once a day; BID: twice a day